Farletuzumab Ecteribulin
Phase 2Small molecule
EisaiFarletuzumab Ecteribulin is one of 5 small molecule programs targeting Antibody-Drug Conjugate. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Antibody-Drug Conjugate
#DrugCompanyPhaseTrials
1Lenvima
EisaiPhase 2
Decadron
AAspen Global Incorporated
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Farletuzumab Ecteribulin
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Farletuzumab Ecteribulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]